Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
Dermatology
•
Nephrology
Have you utilized JAK inhibitors in patients on dialysis?
Related Questions
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
Do you recommend sending an autoimmune work up for patients with recurrent nephrolithiasis and 24 hour urine chemistries consistent with distal renal tubular acidosis?
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
